Literature DB >> 27510238

Ending tuberculosis by 2030: can we do it?

A B Suthar1, R Zachariah2, A D Harries3.   

Abstract

The Sustainable Development Goals aim to end tuberculosis (TB) related deaths, transmission and catastrophic costs by 2030. Multisectorial action to accelerate socio-economic development, a new vaccine and novel diagnostics and medicines for treatment are key advances needed to end TB transmission. Achieving 90-90-90 targets for TB (i.e., 90% of vulnerable populations screened, 90% diagnosed and started on treatment, and at least 90% cured) will help accelerate progress towards reductions in mortality; however, passive case detection strategies, multidrug-resistant TB, human immunodeficiency virus coinfection and outdated pathways to care need to be overcome. Ending the catastrophic costs associated with TB will require expansion of health insurance coverage, comprehensive coverage of TB services, and limited indirect costs by vulnerable and poor populations.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27510238     DOI: 10.5588/ijtld.16.0142

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  11 in total

1.  Time-series analysis of tuberculosis from 2005 to 2017 in China.

Authors:  H Wang; C W Tian; W M Wang; X M Luo
Journal:  Epidemiol Infect       Date:  2018-04-30       Impact factor: 4.434

2.  Priority-Setting for Novel Drug Regimens to Treat Tuberculosis: An Epidemiologic Model.

Authors:  Emily A Kendall; Sourya Shrestha; Ted Cohen; Eric Nuermberger; Kelly E Dooley; Lice Gonzalez-Angulo; Gavin J Churchyard; Payam Nahid; Michael L Rich; Cathy Bansbach; Thomas Forissier; Christian Lienhardt; David W Dowdy
Journal:  PLoS Med       Date:  2017-01-03       Impact factor: 11.069

3.  First reported case of fulminant TB with progression of infection from lungs to the genitourinary region.

Authors:  Tatjana Adzic-Vukicevic; Aleksandra Barac; Aleksandra Dudvarski Ilic; Radmila Jankovic; Jovan Hadzi-Djokic; Dragica Pesut
Journal:  Rev Inst Med Trop Sao Paulo       Date:  2017-04-13       Impact factor: 1.846

4.  How Can Operational Research Help to Eliminate Tuberculosis in the Asia Pacific Region?

Authors:  Anthony D Harries; Ajay M V Kumar; Srinath Satyanarayana; Pruthu Thekkur; Yan Lin; Riitta A Dlodlo; Rony Zachariah
Journal:  Trop Med Infect Dis       Date:  2019-03-15

5.  Assessing the impacts of short-course multidrug-resistant tuberculosis treatment in the Southeast Asia Region using a mathematical modeling approach.

Authors:  Win Min Han; Wiriya Mahikul; Thomas Pouplin; Saranath Lawpoolsri; Lisa J White; Wirichada Pan-Ngum
Journal:  PLoS One       Date:  2021-03-26       Impact factor: 3.240

Review 6.  What can National TB Control Programmes in low- and middle-income countries do to end tuberculosis by 2030?

Authors:  Anthony D Harries; Yan Lin; Ajay M V Kumar; Srinath Satyanarayana; Kudakwashe C Takarinda; Riitta A Dlodlo; Rony Zachariah; Piero Olliaro
Journal:  F1000Res       Date:  2018-07-05

7.  Temporal pattern of tuberculosis cure, mortality, and treatment abandonment in Brazilian capitals.

Authors:  George Jó Bezerra Sousa; Thiago Santos Garces; Maria Lúcia Duarte Pereira; Thereza Maria Magalhães Moreira; Germana Maria da Silveira
Journal:  Rev Lat Am Enfermagem       Date:  2019-12-05

8.  A New Financing Model for Tuberculosis (TB) Care in China: Challenges of Policy Development and Lessons Learned from the Implementation.

Authors:  Qian Long; Weixi Jiang; Di Dong; Jiaying Chen; Li Xiang; Qiang Li; Fei Huang; Henry Lucas; Shenglan Tang
Journal:  Int J Environ Res Public Health       Date:  2020-02-21       Impact factor: 3.390

9.  Factors influencing active tuberculosis case-finding policy development and implementation: a scoping review.

Authors:  Olivia Biermann; Knut Lönnroth; Maxine Caws; Kerri Viney
Journal:  BMJ Open       Date:  2019-12-11       Impact factor: 2.692

10.  Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019.

Authors: 
Journal:  Lancet       Date:  2020-10-17       Impact factor: 202.731

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.